Related Experiment Video

Updated: Jun 19, 2026

An Approach to Study Shape-Dependent Transcriptomics at a Single Cell Level
06:02

An Approach to Study Shape-Dependent Transcriptomics at a Single Cell Level

Published on: November 2, 2020

Regulation of myocardial SERCA2a expression in ventricular hypertrophy and heart failure

Alice Muller1, Warner S Simonides

  • 1Institute for Cardiovascular Research, Laboratory for Physiology, VU University Medical Center, Van der Boechorststraat 7, 1081 BT Amsterdam, The Netherlands.

Future Cardiology
|October 7, 2009
PubMed

Insights

Reduced sarcoplasmic/endoplasmic reticulum calcium ion (Ca2+)-ATPase (SERCA2a) activity impairs heart muscle contraction in heart failure. This review examines how reduced SERCA2a expression, driven by transcriptional changes, causes this dysfunction.

Area of Science:

  • Cardiovascular Physiology
  • Molecular Cardiology
  • Heart Failure Pathophysiology

Background:

  • Diminished cardiomyocyte contractility is key to ventricular dysfunction in chronic heart failure.
  • Reduced activity of the sarcoplasmic/endoplasmic reticulum calcium ion (Ca2+)-ATPase (SERCA2a) contributes significantly to this decline.
  • Decreased SERCA2a activity is implicated in the progression from compensatory hypertrophy to heart failure.

Purpose of the Study:

  • To review the transcriptional regulation of SERCA2a expression in heart failure.
  • To explore the role of signal transduction pathways in pathologic hypertrophy and SERCA2a expression.
  • To discuss potential therapeutic strategies targeting SERCA2a in heart failure.

Main Methods:

  • Literature review focusing on transcriptional regulation of SERCA2a.
  • Analysis of signal transduction pathways in cardiac hypertrophy.
  • Synthesis of current research on therapeutic implications.

Main Results:

  • Transcriptional dysregulation is identified as the primary driver of reduced SERCA2a activity in heart failure.
  • Signal transduction pathways involved in pathologic hypertrophy directly impact SERCA2a expression levels.
  • Understanding these mechanisms highlights potential therapeutic targets.

Conclusions:

  • Transcriptional control of SERCA2a is central to heart failure pathogenesis.
  • Targeting these regulatory pathways offers promising therapeutic avenues for improving cardiac function.
  • Further research into SERCA2a regulation is crucial for developing effective heart failure treatments.

More Related Videos

Assessment of Sarcoplasmic Reticulum Calcium Reserve and Intracellular Diastolic Calcium Removal in Isolated Ventricular Cardiomyocytes11:00

Assessment of Sarcoplasmic Reticulum Calcium Reserve and Intracellular Diastolic Calcium Removal in Isolated Ventricular Cardiomyocytes

Published on: September 18, 2017

Isolation, Culture, and Functional Characterization of Adult Mouse Cardiomyoctyes12:49

Isolation, Culture, and Functional Characterization of Adult Mouse Cardiomyoctyes

Published on: September 24, 2013

Related Concept Videos

Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
Cellular Adaptation II: Hypertrophy01:26

Cellular Adaptation II: Hypertrophy

Hypertrophy is the increase in the size of individual cells, resulting in the enlargement of a tissue or organ. Unlike hyperplasia, which involves an increase in cell number, hypertrophy is characterized by an increase in cell volume. This process often occurs in response to higher functional demand or hormonal stimulation, leading to the production of more structural proteins and organelles, thereby enhancing the cells' work capacity.There are two primary types of hypertrophy: physiological...